Avidity Partners Management LP 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 9:40 pm Sale |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Avidity Partners Management LP | 235,000 0.400% |
-3,590,000 (-93.86%) |
Filing |
| 2023-02-14 2:58 pm Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Avidity Partners Management LP | 3,825,000 8.200% |
720,000 (+23.19%) |
Filing |
| 2022-09-16 10:16 am Purchase |
2022-09-15 | 13G | Akero Therapeutics, Inc. AKRO |
Avidity Partners Management LP | 3,105,000 6.900% |
3,105,000 (New Position) |
Filing |